Sign up
Pharma Capital

THC Global granted manufacturing licence by Australian Office of Drug Control

THC Global Group Ltd (ASX:THC) chief executive officer Ken Charteris updates Proactive Investors on the manufacturing licence granted to the cannabis company by the Australian Office of Drug Control.
 
"It's a significnat milestone ... we now are a farm-to-pharma process which means that we grow, and we actually then process to a complete medicine," says Charteris. 
 
He continues, "This is a great position for us to be in and we're the only company presently that holds the whole suite and also have their own breeds and processing. 
 
"The bigger news for us is that we're a global company - this now allows us to produce and formulate our own brands with our own products."
 

View full THC profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.